The recent preclinical study demonstrated that the ADAM17 inhibitor BMS566394 significantly enhanced the expression of CD16 on NK cells and more importantly, it enhanced the cytotoxic activity and IFN-γ production of treated NK cells combined with trastuzumab against breast cancer cell lines (162). This evidence concerns the gene ADAM17 and breast carcinoma.